FDA approval of a chemo-free lung cancer drug characterized by the Heppner Lab

A study published two years ago by Prof. David Heppner reported the first three-dimensional structures of Lazcluze (Lazertinib). The FDA recently approved this drug administered in combination with Rybrevant (Amivantamab) for the treatment of lung cancer.

Link to Q&A

Link to paper